Compare

Regencell Bioscience/$RGC

1D1W1M3M6MYTD1Y5YMAX

About Regencell Bioscience

Regencell Bioscience Holdings Ltd is an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Its goal is to save and improve the lives of patients, their families and caregivers and become a market leader for the natural and holistic treatment globally. The company operates and manages its business as a single segment - in the research and development of the company's product candidates.
Ticker
$RGC
Sector
Health
Primary listing
NASDAQ
Employees
-
Headquarters
Causeway Bay, Hong Kong
Website
www.regencellbioscience.com

RGC Metrics

BasicAdvanced
$2.7B
-
-$0.02
1.17
-

Bulls say / Bears say

Regencell says it has rights to a standardised TCM formula candidate for ADHD and ASD, giving it a defined pipeline to develop across two indications. The candidates remain experimental and are not approved. (SEC)
The company has reported lower symptom-rating scores in its small second efficacy study, offering an early signal that the formula may warrant further testing. The results are not controlled clinical evidence, so they do not establish that the treatment works. (SEC)
A May 2026 share offering brought in about $20 million, led by a $19 million investment, providing fresh capital to support research and operations. That funding could give the company more scope to advance its candidates before seeking further capital. (SEC)
The efficacy evidence is preliminary: the second study is small, lacks a control group and remains ongoing, while Regencell has not applied for product approval. The company says the study may need redesign, which could delay development further. (SEC)
Regencell has no product-sales revenue and reported a fiscal 2026 net loss of $11.7 million, up from $3.58 million the year before. Continued losses leave the business reliant on external funding before it has a commercial product. (SEC)
The company is still cooperating with a US Department of Justice investigation into trading in its shares, and its auditor reported material weaknesses in internal controls. The probe’s outcome and the controls issues create legal, reporting and confidence risks. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.

RGC Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.